TCGX

10.0200.05%
WL

Wei Lin

Independent Director

Dr. Wei Lin, MD, Ph.D., is Independent Director of TCGX Acquisition Corp. from August 4, 2026. Dr. Lin is Chief Medical Officer at Revolution Medicines, Inc. since May 2023. He oversees clinical strategy and medical affairs. He was Director at 2seventy bio, Inc. from March 08, 2023 until May 13, 2025. He led early-stage and late-stage cancer drug development programs during a career at Genentech, Nektar and Erasca. He served as Chief Medical Officer of Erasca, Inc. since January 2021 until April 21, 2023. Dr. Lin served as Senior Vice President and Head of Development at Nektar Therapeutics since 2019 until January 5, 2021 and also served as its Senior Vice President of Clinical Development and Head from his joining in November 14, 2018 until 2019. Prior to joining Nektar, Dr. Lin served as the Global Development Leader for cancer immunotherapy in lung and Head and neck cancer at Genentech from 2011 to 2018. During his tenure at Genentech, he held several senior leadership positions of increasing responsibility including Global Clinical Leader of Cancer Immunotherapy in lung and Head and neck cancer, where he led a team of 20 medical Directors and clinical scientists and directed clinical development strategy for cancer immunotherapy in lung cancer and executed registration trials in lung cancer and Head and neck cancer including the successful readouts of five Phase 3 trials in first-line lung cancer and regulatory filing of three of these trials. In addition, he also served as the Site Head for Oncology Development in Roche Asia Pacific and oversaw the regulatory approval of three oncology products in China. He was also the site Head for oncology product development for Roche China, where his team achieved multiple additional regulatory approvals for Avastin®, Zelboraf® and Tarceva®. Prior to Genentech, Dr. Lin was a faculty Member at M. D. Anderson Cancer Center in Houston in the Department of Thoracic/Head and Neck Medical Oncology. Dr. Lin has extensive clinical research experience and has been published in more than 15 peer-reviewed journals. He received a B. A. in physics from Haverford College and an M. D. from Harvard Medical School. Dr. Lin completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M. D. Anderson Cancer Center.

Positions